Metrics as of 10/17/2026, 09:25 AM (Berlin time), refresh in progress.
Regentis Biomaterials Stock
Regentis Biomaterials Ltd.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- Israel
- CEO
- Ehud Geller
- Employees
- 10
- Market cap
- $10 M
- IPO
- 04/12/2025
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be…
Regentis Biomaterials stock: price history
1D
-3.9%
1W
-6.9%
1M
-17.2%
6M
-51.1%
YTD
-77.9%
1Y
–
2Y
–
5Y
–
10Y
–
Ask the agents about Regentis Biomaterials
Free float & liquidity
FREE FLOAT
44.4%
FLOAT SHARES
3,121,714
AVG. DAILY VOLUME (30D)
55,498
Comparable stocks
Frequently asked questions about Regentis Biomaterials stock
What does Regentis Biomaterials do?
Regentis Biomaterials Ltd. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in Israel.
The CEO is Ehud Geller, the company employs around 10 people.
The IPO was on 04/12/2025; the stock trades on AMEX under the ticker RGNT.
Does Regentis Biomaterials pay a dividend?
No, Regentis Biomaterials currently does not pay a dividend.
Which stocks are comparable to Regentis Biomaterials?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Sartorius, Solventum, Baxter International and Cooper Companies.
How can I get Regentis Biomaterials stock analyzed?
Clicking "Analyze stock" lets five strategies assess Regentis Biomaterials against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.